How many stem-cell trials for Liver Cirrhosis are recruiting right now?
Right now 6 of 89 records (7%) carry recruiting status; the rest are completed, finished enrolling or stopped. Snapshot 2026-08-29.
Who these studies will actually take
Eligibility hangs on Child-Pugh or MELD scores, absence of active infection or hepatocellular carcinoma, and often continued abstinence in alcohol-related disease. Many people searching are outside the band in both directions: too compensated to justify risk, or too decompensated to enrol.
The studies currently enrolling
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07413549 — Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis | Phase 1, Phase 2 | Recruiting | 76 | Beijing Tuohua Weiye Biotechnology Co., Ltd. | 2025-02-25 |
| NCT04689152 — Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis | Phase 3 | Recruiting | 200 | Pharmicell Co., Ltd. | 2021-03-02 |
| NCT03826433 — hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis | Phase 1 | Recruiting | 20 | Sclnow Biotechnology Co., Ltd. | 2018-10-01 |
| NCT05224960 — Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) | Phase 2 | Recruiting | 140 | Beijing 302 Hospital | 2024-06-27 |
| NCT06564740 — Stem Cell Applications in Biliary Atresia Patients | n/a | Recruiting | 64 | Necmi Kadıoğlu Hospital | 2024-06-01 |
| NCT07028112 — Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantati | n/a | Recruiting | 500 | Assistance Publique - Hôpitaux de Paris | 2025-08-20 |
What recruiting does and does not mean
Open enrolment is an administrative state, not a clinical endorsement. Sponsors register before recruiting, keep records open through slow periods and close them late. Read the eligibility section and the last-update date together before drawing any conclusion.
Sites sit in 19 countries, led by China. Travelling for a trial rarely works unless the site has confirmed in writing that it can enrol non-residents and fund the follow-up schedule.
Who is running the studies here
Lead sponsors appearing most often for this condition. Useful for one specific check: whether the entity quoting research at you appears anywhere in it.
- Beijing 302 Hospital — 7 registered records
- Vinmec Research Institute of Stem Cell and Gene Technology — 4 registered records
- General Hospital of Shenyang Military Region — 3 registered records
- Sun Yat-sen University — 3 registered records
- Pharmicell Co., Ltd. — 3 registered records
- Air Force Military Medical University, China — 3 registered records
Frequently asked
How many stem-cell trials for Liver Cirrhosis are recruiting right now?
6 of 89 registered records (2026-08-29).
Can I join one of these trials?
That depends entirely on the written criteria — age, disease stage, prior treatment and often geography. The site's study coordinator is the only reliable source on current capacity.
Do trials charge participants?
Trial participation is normally free of charge for the intervention under study; some studies even reimburse travel. Payment demands invert that relationship and should stop the conversation.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Liver Cirrhosis: cell-therapy evidence and registered trials
- How much does stem cell therapy for Liver Cirrhosis cost? (2026)
- Liver Cirrhosis stem cell therapy — your questions answered (2026)
- Liver Cirrhosis: cell-therapy evidence by therapy class
- MSC vs HSCT for Liver Cirrhosis: what the registries show